Monte Rosa Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $123.7 | $75.6 | $0.0 | — | — |
| Operating income | -$54.2 | -$81.1 | -$143.3 | -$112.4 | -$72.9 |
| Net income | -$38.6 | -$72.7 | -$135.4 | -$108.5 | -$74.0 |
| Cash Flow Statement | |||||
| Free cash flow | -$27.5 | $38.0 | -$62.8 | -$105.4 | -$69.1 |
| Dividends | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 |
Shares outstanding 85.3M · Free float 78.8%
Annual filing data through FY ended December 31, 2025; float as of October 5, 2026.